Pertussis immunization in the global pertussis initiative international region: recommended strategies and implementation considerations.

Search TravelDoctorOnline

Authors: Forsyth K,Nagai M,Lepetic A,Trindade E,
Address: Department of Paediatrics, Flinders Medical Centre, Flinders University, Adelaide, Australia. Kevin.Forsyth@flinders.edu.au
Journal: Pediatr Infect Dis J.


Publication: 2005 May;24(5 Suppl):S93-7.

abstract

Despite widespread immunization programs in most countries, pertussis disease continues to be a threat to public health. In particular, there has been a resurgence of pertussis disease in older children, adolescents and adults, creating a reservoir of infection, which poses a significant threat to infants who are either unimmunized or incompletely immunized. global Pertussis initiative participants from Argentina, Australia, Brazil and Japan considered the relative merits of several strategies to reduce the burden of pertussis disease and suggested strategies that might be implemented in these countries. Infants in these countries receive an initial course of 3 doses of vaccine in the first year of life followed by a fourth dose in the second year. Only children in Japan are not given a preschool booster (age 3-5 years). Of the strategies considered, the addition of a preschool booster is therefore a priority in Japan to overcome the problem of waning vaccine-induced immunity to pertussis in school children. Waning immunity also affects adolescents; Australia introduced an adolescent booster in 2003, and the addition of a booster in this age group was suggested for Argentina and Japan. Immunization of new mothers and other close contacts of young infants, such as child care and health care workers, might be appropriate in Australia in the future. Argentina also suggested a future possibility of immunizing health care and child care workers. Obstacles to new immunization strategies include poor access to standardized laboratory diagnostic techniques, inadequate resources to fund new immunization programs, low awareness of pertussis disease in adults and adolescents and inadequate surveillance techniques to assess the full extent of the problems caused by pertussis or the impact new vaccination strategies might have.



Related Articles
Review Pertussis immunization in the global pertussis initiative North American region: recommended strategies and implementation considerations.
Pediatr Infect Dis J. 2005
Review Pertussis immunization in the global pertussis initiative North American region: recommended strategies and implementation considerations.
Tan T, Halperin S, Cherry JD, Edwards K, Englund JA, Glezen P, Greenberg D, Rothstein E, Skowronski D. Pediatr Infect Dis J. 2005 May; 24(5 Suppl):S83-6.
Review Pertussis immunization in the global pertussis initiative European region: recommended strategies and implementation considerations.
Pediatr Infect Dis J. 2005
Review Pertussis immunization in the global pertussis initiative European region: recommended strategies and implementation considerations.
Wirsing von König CH, Campins-Marti M, Finn A, Guiso N, Mertsola J, Liese J. Pediatr Infect Dis J. 2005 May; 24(5 Suppl):S87-92.
Review Epidemiology of pertussis.
Pediatr Infect Dis J. 2005
Review Epidemiology of pertussis.
Tan T, Trindade E, Skowronski D. Pediatr Infect Dis J. 2005 May; 24(5 Suppl):S10-8.
Review Potential strategies to reduce the burden of pertussis.
Pediatr Infect Dis J. 2005
Review Potential strategies to reduce the burden of pertussis.
Forsyth K, Tan T, von König CH, Caro JJ, Plotkin S. Pediatr Infect Dis J. 2005 May; 24(5 Suppl):S69-74.
Review Pertussis sources of infection and routes of transmission in the vaccination era.
Pediatr Infect Dis J. 2005
Review Pertussis sources of infection and routes of transmission in the vaccination era.
Schellekens J, von König CH, Gardner P. Pediatr Infect Dis J. 2005 May; 24(5 Suppl):S19-24.
Development and analytical validation of an immunoassay for quantifying serum anti-pertussis toxin antibodies resulting from Bordetella pertussis infection.
Clin Vaccine Immunol. 2009
Development and analytical validation of an immunoassay for quantifying serum anti-pertussis toxin antibodies resulting from Bordetella pertussis infection.
Menzies SL, Kadwad V, Pawloski LC, Lin TL, Baughman AL, Martin M, Tondella ML, Meade BD, Pertussis Assay Working Group. Clin Vaccine Immunol. 2009 Dec; 16(12):1781-8. Epub 2009 Oct 28.
Proficiency program for real-time PCR diagnosis of Bordetella pertussis infections in French hospital laboratories and at the French National Reference Center for Whooping Cough and other Bordetelloses.
J Clin Microbiol. 2009
Proficiency program for real-time PCR diagnosis of Bordetella pertussis infections in French hospital laboratories and at the French National Reference Center for Whooping Cough and other Bordetelloses.
Caro V, Guiso N, Alberti C, Liguori S, Burucoa C, Couetdic G, Doucet-Populaire F, Ferroni A, Papin-Gibaud S, Grattard F, et al. J Clin Microbiol. 2009 Oct; 47(10):3197-203. Epub 2009 Aug 19.
Is the Sequenced Bordetella pertussis strain Tohama I representative of the species?
J Clin Microbiol. 2008
Is the Sequenced Bordetella pertussis strain Tohama I representative of the species?
Caro V, Bouchez V, Guiso N. J Clin Microbiol. 2008 Jun; 46(6):2125-8. Epub 2008 Apr 2.

To top Home


Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.